|
|
 |
December 15, 2011
FDA Will Not Require a Risk Evaluation and Mitigation Strategy in Connection With Corcept's Proposed Distribution of Korlym™ for Cushing's Syndrome
December 14, 2011
Amarin Announces the Addition of Industry Veteran Patrick O'Sullivan to Board
December 14, 2011
Blood-Based Gene Expression Test Beats MPI for Ruling Out Obstructive CAD
December 12, 2011
Aptus Endosystems Completes First HeliFX™ Procedures in US
December 7, 2011
'Smartphone glasses' are unlike anything you've seen Before
November 25, 2011
Amarin Announces FDA Acceptance for Filing of AMR101 NDA
November 22, 2011
Cadence Pharmaceuticals Announces Completion of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
November 22, 2011
NxStage Enhances Patient Awareness Efforts with Launch of Online Nephrologist Directory To Help Patients Connect with Local System One Prescribers
November 21, 2011
Amarin Added to NASDAQ Biotechnology Index
November 21, 2011
Aptus Receives FDA Clearance for HeliFX™ System
November 15, 2011
CardioDx Blood-Based Gene Expression Test Demonstrates Superior Performance to Myocardial Perfusion Imaging to Rule Out Obstructive Coronary Artery Disease
November 1, 2011
Solta and Medicis Announce Close of Agreement For LipoSonix
October 10, 2011
Longitude Capital Named the Top Performer in the Colorado PERA Venture Portfolio
October 10, 2011
James Tobin, Former CEO of Boston Scientific, Joins Aptus Board of Directors
September 26, 2011
Amarin Announces NDA Submission for AMR101 to Treat Patients With Very High Triglycerides
September 19, 2011
CardioDx Appoints Andrew Guggenhime as Chief Financial Officer and Mark Monane, M.D., as Chief Medical Officer
September 19, 2011
Jazz Pharmaceuticals and Azur Pharma Agree to Combine to Form Jazz Pharmaceuticals plc
September 13, 2011
Medicis and Solta Announce Agreement for LipoSonix
September 1, 2011
Amarin Announces Successful MARINE Phase 3 Clinical Trial Results
August 10, 2011
Amarin Announces Agreement on Special Protocol Assessment for AMR101 Outcomes Study
July 12, 2011
Civitas Therapeutics secures $5M in financing
July 12, 2011
Barry M. Straube, M.D., Former Medicare Official and Leader of Major Quality and Policy Initiatives in Nephrology, Joins NxStage Board of Directors
June 17, 2011
NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the YearŽ 2011 New England Award Winner
June 30, 2011
FDA Accepts Submission of New Drug Application for CORLUX for Cushing's Syndrome
June 6, 2011
Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx in Directing Chemotherapy in Gynecologic Cancers
June 4, 2011
Corcept Therapeutics Announces Detailed Findings from Phase 3 Study
May 23, 2011
Aptus Endosystems Receives CE Mark for EndoStapling System
May 11, 2011
CardioDx Completes $60 Million in Equity Financing
May 6, 2011
Solta Medical Announces FDA 510(k) Clearance for NEW Clear + Brilliant Technology
April 30, 2011
PixelOptics Launches emPower!
April 18, 2011
Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints
April 18, 2011
Precision Therapeutics Partners with Med Biogene to Commercialize LungExpress DX
April 7, 2011
PixelOptics Closes $45 Million Financing
April 7, 2011
Precision Therapeutics Announces New Tumor Profiling Product
April 5, 2011
New Multi-center Trial Results Demonstrate Ability of the CardioDx Corus CAD to Identify Obstructive Coronary Artery Disease and Add Independent Information to Coronary Calcium Scoring by CT Angiography
March 7, 2011
CardioDx Raises $40 Million
February 16, 2011
Fox Business Profiles PixelOptics' High Tech Eyeglasses
February 12, 2011
The New York Times Article on PixelOptics: Have You Charged Your Eyeglasses Today?
February 3, 2011
Solta Medical Introduces Two New Products at The American Academy of Dermatology
January 26, 2011
Corcept Therapeutics Announces Closing of $44.9 Million Underwritten Public Offering of Common Stock
January 19, 2011
Precision Therapeutics Announces Two Pancreatic Cancer Studies Emphasizing the Utility of ChemoFx in Cancer Treatment Options
January 18, 2011
PixelOptics' emPower! Featured on "Live! With Regis and Kelly"
January 11, 2011
Amarin Announces Successful Completion of Offering of American Depositary Shares
January 11, 2011
Corcept Therapeutics Announces Key Secondary Endpoint Was Met in Phase 3 Study of CORLUX for Cushing's Syndrome
January 10, 2011
emPower! Electronic Focusing Eyeglasses Receives International Recognition at the 2011 Consumer Electronics Show
January 10, 2011
Civitas Therapeutics Secures $20 Million Series A Financing
|
|
|
